OBJECTIVES: Finasteride reduced the risk of prostate cancer by 24.8% in the Prostate
Cancer Prevention Trial (PCPT). Whether this represents treatment or prevention and who is …

Purpose Finasteride has been shown to reduce the incidence of prostate cancer. Yet the use
of finasteride remains low, likely because of the risk of adverse effects. We sought to …

Purpose: Prostate cancer is the most common male cancer, affecting one man in six.
Prevention of this disease, even in a subset of patients would have a significant impact on …

The PCPT demonstrated that 7 years of prophylactic treatment with finasteride reduced the
risk of prostate cancer by 6%(from 24.4% in the placebo group to 18.4% in the finasteride …

Although testosterone is the major circulating andro-gen in men, dihydrotestosterone (DHT)
is more potent and is the major form of androgen found within the prostate gland. 1 DHT …

Background: Finasteride has been found to reduce the risk of low-grade prostate cancer but
to have no impact on overall survival. The long-term adverse and beneficial consequences …

Background In the Prostate Cancer Prevention Trial (PCPT), finasteride reduced the
prevalence of prostate cancer compared with placebo; however, the proportion of high …

78.0% in the finasteride group compared with 78.2% in the placebo group. Survival rates
were also comparable after 10 years, even when men were classified according to cancer …

In an article in the August 10th issue, NCI Director Andrew von Eschenbach, MD, when
asked if the Prostate Cancer Prevention Trial (PCPT) had sent some mixed cancer …

Finasteride and Prostate Cancer: A Commentary | The Oncologist | Oxford Academic Skip to
Main Content Advertisement Oxford Academic Journals Books Search Menu Information …